<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Tetanus-Diphtheria Vaccine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Tetanus-Diphtheria Vaccine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Vaccines</div>
      <h1>Tetanus-Diphtheria Vaccine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Tetanus-Diphtheria Vaccine 0.5mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Routine booster (primary series previously completed)</strong>
            <ul>
              <li>0.5 mL IM every 10 years</li>
              <li>Tdap (tetanus-diphtheria-acellular pertussis) preferred for one dose in adulthood; subsequent boosters may be Td</li>
            </ul>
          </li>
          <li><strong>Wound management (tetanus prophylaxis)</strong>
            <ul>
              <li><strong>Clean, minor wounds:</strong></li>
              <ul>
                <li>If last dose &gt;10 years ago: give Td or Tdap (0.5 mL IM)</li>
                <li>If &lt;3 doses in lifetime or unknown history: complete primary series</li>
              </ul>
              <li><strong>Contaminated, deep, or high-risk wounds (puncture, crush, burn, soil contamination):</strong></li>
              <ul>
                <li>If last dose &gt;5 years ago OR &lt;3 doses/unknown history: give Td or Tdap (0.5 mL IM)</li>
                <li>If &lt;3 doses in lifetime or unknown history: also consider tetanus immunoglobulin (TIG) per protocol</li>
              </ul>
            </ul>
          </li>
          <li><strong>Primary immunization series (previously unvaccinated or incomplete series)</strong>
            <ul>
              <li>0.5 mL IM at 0, 4–8 weeks, and 6–12 months (3-dose series)</li>
              <li>Tdap preferred for one dose; complete series with Td</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Routine tetanus and diphtheria booster immunization in adults</li>
          <li>Tetanus prophylaxis following injury (wound management)</li>
          <li>Completion of primary immunization series in previously unvaccinated or incompletely vaccinated adults</li>
          <li>Post-exposure prophylaxis for diphtheria (in outbreak settings, per public health guidance)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Severe allergic reaction (anaphylaxis) to previous dose of tetanus or diphtheria toxoid-containing vaccine</li>
          <li>Encephalopathy within 7 days of previous dose (pertussis component; relevant if Tdap used)</li>
          <li>Progressive neurologic disorder (defer until stabilized)</li>
          <li>Moderate to severe acute illness (defer until recovered; minor illness not a contraindication)</li>
          <li>History of Arthus reaction or severe local reaction following previous dose: defer booster for at least 10 years</li>
          <li>Pregnancy: Tdap recommended in each pregnancy (ideally 27–32 weeks) to provide passive immunity to infant; Td generally safe if needed</li>
          <li>Immunocompromised patients: may receive vaccine but response may be reduced</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Local reactions (very common): pain, redness, swelling at injection site</li>
          <li>Systemic reactions: headache, fatigue, myalgia, fever (usually mild and self-limited)</li>
          <li>Severe local reactions (Arthus-type hypersensitivity): extensive limb swelling, severe pain (more common with frequent boosters; typically occurs if given too frequently)</li>
          <li>Rare: anaphylaxis, brachial neuritis, Guillain-Barré syndrome (extremely rare; causal relationship uncertain)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Shake vial/syringe well before use (suspension; do not use if particulate matter or discoloration present)</li>
          <li>Administer 0.5 mL IM (deltoid muscle preferred in adults)</li>
          <li>Use aseptic technique; do not inject into same site as other vaccines (if multiple vaccines given)</li>
          <li>Do not administer IV, subcutaneous, or intradermal</li>
          <li>Document vaccine name, lot number, date, site of administration, and patient immunization history</li>
          <li>Observe patient for 15 minutes post-vaccination for immediate allergic reactions</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Immediate monitoring for 15 minutes post-vaccination (anaphylaxis, syncope risk)</li>
          <li>Local and systemic reactions (counsel patient on expected side effects and when to seek care)</li>
          <li>If severe local reaction occurs, note in immunization record and defer future boosters appropriately</li>
          <li>Wound healing and signs of tetanus (if administered for wound prophylaxis; tetanus symptoms include muscle rigidity, jaw spasm, difficulty swallowing)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Wound management priority: early wound cleansing and debridement reduce tetanus risk; vaccine is adjunct to proper wound care</li>
          <li>Immunization history critical: attempt to confirm prior doses with patient/medical records; if unknown, err on side of administration (especially for high-risk wounds)</li>
          <li>Tetanus immunoglobulin (TIG): if indicated for high-risk wounds and patient unvaccinated/unknown history, consult medical direction; TIG may not be stocked onboard</li>
          <li>Storage: vaccine requires refrigeration (2–8°C); do not freeze; ensure cold chain maintained in maritime environment</li>
          <li>Document clearly: record lot number, expiry date, dose, and indication for medico-legal and continuity of care purposes</li>
          <li>Evacuation planning: if severe wound with inadequate immunization history and no TIG available, consider evacuation for comprehensive management</li>
          <li>Functional impact: warn patient of potential arm soreness; may affect work duties for 24–48 hours</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Public Health Agency of Canada – Canadian Immunization Guide (Tetanus): <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-7-diphtheria-vaccine.html" target="_blank" rel="noopener">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-7-diphtheria-vaccine.html</a></li>
          <li>Public Health Agency of Canada – Tetanus prophylaxis in wound management: <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-15-tetanus-toxoid.html" target="_blank" rel="noopener">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-15-tetanus-toxoid.html</a></li>
          <li>Health Canada product monograph (Td Adsorbed / Td Polio Adsorbed): <a href="https://pdf.hres.ca/dpd_pm/00070633.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00070633.PDF</a></li>
          <li>CDC Tetanus Clinical Information: <a href="https://www.cdc.gov/tetanus/clinicians.html" target="_blank" rel="noopener">https://www.cdc.gov/tetanus/clinicians.html</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
